/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

AIM ImmunoTech Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.4 0.0072(0.72%) AIM at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 1.35
Highest Today 1.41
Today’s Open 1.4
Prev. Close 1.39
52 Week High 25.40
52 Week Low 1.26
Day’s Range: Low 1.35 High 1.41
52-Week Range: Low 1.26 High 25.40
1 day return -
1 Week return -7.89
1 month return -12.5
3 month return -41.66
6 month return -86.27
1 year return +596.51
3 year return +250.0
5 year return -29.29
10 year return -

Institutional Holdings

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 3.97 M

PB Ratio 2.7248

PE Ratio 0.0

Enterprise Value 4.35 M

Total Assets 8.61 M

Volume 26788

Company Financials

Annual Revenue FY23:202000 0.2M, FY23:141000 0.1M, FY22:135000 0.1M, FY21:163000 0.2M, FY20:140000 0.1M

Annual Profit FY23:-78000 -0.1M, FY23:-19782000 -19.8M, FY22:-715000 -0.7M, FY21:-643000 -0.6M, FY20:-753000 -0.8M

Annual Net worth FY23:-28962000 -29.0M, FY23:-21086000 -21.1M, FY22:-21513000 -21.5M, FY21:-16258000 -16.3M, FY20:-10826000 -10.8M

Quarterly Revenue Q3/2025:26000 0.0M, Q2/2025:25000 0.0M, Q1/2025:16000 0.0M, Q3/2024:35000 0.0M, Q2/2024:50000 0.1M

Quarterly Profit Q3/2025:-96000 -0.1M, Q2/2025:15000 0.0M, Q1/2025:6000 0.0M, Q3/2024:27000 0.0M, Q2/2024:42000 0.0M

Quarterly Net worth Q3/2025:-3284000 -3.3M, Q2/2025:-2794000 -2.8M, Q1/2025:-3705000 -3.7M, Q3/2024:-3700000 -3.7M, Q2/2024:-1836000 -1.8M

Fund house & investment objective

Company Information AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Organisation Biotechnology

Employees 21

Industry Biotechnology

CEO Mr. Thomas K. Equels Esq., J.D., M.S.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow